| Identification | Back Directory | [Name]
Mecasermin | [CAS]
68562-41-4 | [Synonyms]
Mecasermin
myotrophin
MECASERMIN（INCRELEX）
Insulin-like Growth factor-I, Human, recombinant, Animal-derived-free |
| Chemical Properties | Back Directory | [form ]
Liquid | [color ]
Colorless to light yellow | [Sequence]
Gly-Pro-Glu-Thr-Leu-Cys-Gly-Ala-Glu-Leu-Val-Asp-Ala-Leu-Gln-Phe-Val-Cys-Gly-Asp-Arg-Gly-Phe-Tyr-Phe-Asn-Lys-Pro-Thr-Gly-Tyr-Gly-Ser-Ser-Ser-Arg-Arg-Ala-Pro-Gln-Thr-Gly-Ile-Val-Asp-Glu-Cys-Cys-Phe-Arg-Ser-Cys-Asp-Leu-Arg-Arg-Leu-Glu-Met-Tyr-Cys-Ala-Pro-Leu-Lys-Pro-Ala-Lys-Ser-Ala (Disulfide bridge:Cys6-Cys48;Cys18-Cys61;Cys47-Cys52) |
| Hazard Information | Back Directory | [Uses]
Treatment of amyotrophic lateral
sclerosis; treatment of diabetes mellitus (types I and II);
treatment of growth hormone insensitivity (GHIS). | [Brand name]
Myotrophin (Cephalon-Chiron) [Note—Mecasermin has appeared in the literature as somatomedin-C, IGF-I, and
rhIGF-1.]. | [in vivo]
Mecasermin (rhIGF1; 0.25 mg/kg; i.p.; daily; 6 weeks) increases IGF1 concentration in serum to near-normal levels and ameliorates a wide range of phenotypes, including organismal and behavioral function, synaptic and circuit plasticity, neuronal structure, and molecular signaling pathways[2]. | Animal Model: | Mecp2 hemizygous KO mice[2] | | Dosage: | 0.25 mg/kg | | Administration: | i.p.; daily; 6 weeks | | Result: | Improved lifespan, locomotor activity, heart rate, respiration patterns, and social and anxiety behavior. |
|
|
|